2012
How Do Perceptions About Cessation Outcomes Moderate the Effectiveness of a Gain-Framed Smoking Cessation Telephone Counseling Intervention?
Latimer-Cheung AE, Fucito LM, Carlin-Menter S, Rodriguez J, Raymond L, Salovey P, Makuch R, Cummings KM, Toll BA. How Do Perceptions About Cessation Outcomes Moderate the Effectiveness of a Gain-Framed Smoking Cessation Telephone Counseling Intervention? Journal Of Health Communication 2012, 17: 1081-1098. PMID: 22765277, PMCID: PMC3644974, DOI: 10.1080/10810730.2012.665420.Peer-Reviewed Original ResearchConceptsState quitlineSmoking cessation counselingTelephone counseling interventionSmoking cessation messagesCessation counselingOutcome expectanciesSmoking statusSmoking cessationCessation messagesQuit statusHealth messagesSecondary analysisSmokers' beliefsCare messagesQuitlineIndividual perceptionsCounseling conditionCounseling interventionPreventionMenPositive outcome expectanciesInterventionOutcomesExpectancyIndividual differences
2010
Nicotine dependence as a moderator of a quitline-based message framing intervention
Fucito LM, Latimer AE, Carlin-Menter S, Salovey P, Cummings KM, Makuch RW, Toll BA. Nicotine dependence as a moderator of a quitline-based message framing intervention. Drug And Alcohol Dependence 2010, 114: 229-232. PMID: 21036492, PMCID: PMC3044773, DOI: 10.1016/j.drugalcdep.2010.09.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultCounselingFemaleFollow-Up StudiesHotlinesHumansMaleMiddle AgedSmoking CessationTobacco Use DisorderConceptsMessage framing interventionsNicotine dependence scoresGain-framed messagesNicotine dependenceDependence scoresMore cigarettesPoint prevalence smoking abstinenceNew York State Smokers' QuitlineSmoking cessation treatmentHigh nicotine dependenceState Smokers' QuitlineBaseline total scoreHigher nicotine dependence scoresNicotine dependence levelHigher dependence scoresNicotine medicationsNicotine patchCessation treatmentDependent smokersSmoking abstinenceSmokersSmoking outcomesTotal scoreFraming interventionQuitlineLow-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial
Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O’Malley S. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug And Alcohol Dependence 2010, 111: 200-206. PMID: 20542391, PMCID: PMC3771701, DOI: 10.1016/j.drugalcdep.2010.04.015.Peer-Reviewed Original ResearchConceptsWeight gainSmoking cessationPoint prevalence smoking abstinence ratePre-specified primary outcomesLow-dose naltrexoneOpen-label therapySmoking abstinence ratesPoint prevalence abstinenceReduced weight gainNaltrexone augmentationPlacebo groupNicotine replacementPrimary outcomeQuit dateAbstinence ratesLabel therapyNicotine patchBehavioral counselingNaltrexoneAbstinent participantsSmokersWeight concernsWeeksCessationLower rates
2009
Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis
Qamar AA, Grace ND, Groszmann RJ, Garcia–Tsao G, Bosch J, Burroughs AK, Ripoll C, Maurer R, Planas R, Escorsell A, Garcia–Pagan J, Patch D, Matloff DS, Makuch R, Rendon G, Group P. Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. Clinical Gastroenterology And Hepatology 2009, 7: 689-695. PMID: 19281860, PMCID: PMC4545534, DOI: 10.1016/j.cgh.2009.02.021.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientHematologic indicesCompensated cirrhosisBaseline hepatic venous pressure gradientWhite blood cell countChild-Pugh scorePredictors of deathPrimary end pointVenous pressure gradientDevelopment of varicesKaplan-Meier analysisBlood cell countCombination of leukopeniaBaseline thrombocytopeniaVariceal bleedingClinical decompensationEsophageal varicesPrognostic significanceTransplant surgeryClinical significanceLeukopeniaThrombocytopeniaCirrhosisCell countVarices
2000
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal N, Stenson W, Burr A, Zhao W, Kent J, Lefkowith J, Verburg K, Geis G. Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial. JAMA 2000, 284: 1247-1255. PMID: 10979111, DOI: 10.1001/jama.284.10.1247.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidAspirinCelecoxibCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDiclofenacDouble-Blind MethodFemaleGastrointestinal DiseasesHumansIbuprofenIsoenzymesMaleMembrane ProteinsMiddle AgedOsteoarthritisPeptic UlcerProportional Hazards ModelsProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesSulfonamidesConceptsNonsteroidal anti-inflammatory drugsConventional nonsteroidal anti-inflammatory drugsCelecoxib Long-term Arthritis Safety StudyCOX-2-specific inhibitorsUlcer complicationsSymptomatic ulcersAnti-inflammatory drugsRheumatoid arthritisIncidence rateAspirin useLower incidenceChronic GI blood lossToxic effectsAdverse effectsCelecoxib-treated patientsUpper GI toxicityUpper GI ulcersGI blood lossInhibition of cyclooxygenaseGI intoleranceCardiovascular eventsGastrointestinal toxicityGI toxicityImportant toxic effectsStudy drugUpper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen W, Zhao S, Burke T, Zabinski R, Makuch R, Maurath C, Agrawal N, Geis G. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. The Journal Of Rheumatology 2000, 27: 1876-83. PMID: 10955327.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDouble-Blind MethodDyspepsiaFemaleHumansIsoenzymesMaleMembrane ProteinsMiddle AgedNaproxenNauseaOsteoarthritisProspective StudiesProstaglandin-Endoperoxide SynthasesPyrazolesRisk FactorsSulfonamidesTime FactorsTreatment OutcomeConceptsUpper gastrointestinal tolerabilityUpper GI symptomsSevere abdominal painComposite endpointAbdominal painGastrointestinal tolerabilityGI symptomsIndependent predictorsRheumatoid arthritisRelative riskCOX-2-specific inhibitorsUpper GI tolerabilityTreatment group patientsDose-response relationshipGI tolerabilityPlacebo patientsGroup patientsCumulative incidenceParallel groupClinical trialsPlaceboPatientsCelecoxibTolerabilityEndpointBlood Pressure Exceeding National Guidelines Among Women After Stroke
Kernan W, Viscoli C, Brass L, Makuch R, Sarrel P, Horwitz R. Blood Pressure Exceeding National Guidelines Among Women After Stroke. Stroke 2000, 31: 415-419. PMID: 10657415, DOI: 10.1161/01.str.31.2.415.Peer-Reviewed Original ResearchConceptsHistory of hypertensionBlood pressure valuesNational guidelinesBlood pressureFirst examinationTrial of estrogenSecondary stroke preventionTransient ischemic attackBlood pressure controlTreatment of hypertensionProportion of womenIschemic attackSevere hypertensionStroke preventionSecondary preventionDiabetic patientsMean ageHypertensionPatientsPressure valuesPersonal physicianPressure controlSeparate guidelinesStrokeWomenThe Stroke Prognosis Instrument II (SPI-II)
Kernan W, Viscoli C, Brass L, Makuch R, Sarrel P, Roberts R, Gent M, Rothwell P, Sacco R, Liu R, Boden-Albala B, Horwitz R. The Stroke Prognosis Instrument II (SPI-II). Stroke 2000, 31: 456-462. PMID: 10657422, DOI: 10.1161/01.str.31.2.456.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansIschemic Attack, TransientMaleMiddle AgedPredictive Value of TestsPrognosisStrokeConceptsRisk groups ICongestive heart failurePooled rateRisk groupsGroup IPrior strokeSPI-IIHeart failureOutcome ratesTest cohortPooled outcome ratesTransient ischemic attackCoronary artery diseasePatient risk groupsStroke Prognosis Instrument IIReceiver operator characteristic analysisOperator characteristic analysisIschemic attackIschemic strokeArtery diseaseIndex eventPatient counselingNew predictive variablesStrokeTotal score
1998
Verapamil use in patients with cardiovascular disease: An overview of randomized trials
Pepine C, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: An overview of randomized trials. Clinical Cardiology 1998, 21: 633-641. PMID: 9755379, PMCID: PMC6655547, DOI: 10.1002/clc.4960210906.Peer-Reviewed Original ResearchConceptsMyocardial infarctionVerapamil useNonfatal reinfarctionCalcium antagonistsDecreased riskDrug classesCardiovascular diseaseCertain calcium antagonistsNonfatal myocardial infarctionOutcome of deathParallel-group studyStandard meta-analytic techniquesRandomized clinical trialsAcute myocardial infarctionEnglish-language articlesEvidence of harmAngina StudyHypertensive patientsOverall mortalityRandomized studyRandomized trialsTrial characteristicsClinical trialsPatient outcomesMEDLINE search
1996
Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation
Horwitz R, Singer B, Makuch R, Viscoli C. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. Journal Of Clinical Epidemiology 1996, 49: 395-400. PMID: 8621989, DOI: 10.1016/0895-4356(95)00058-5.Peer-Reviewed Original ResearchConceptsClinical inquiryBeta-Blocker Heart Attack TrialCoronary artery surgeryHeart Attack TrialSubgroup of patientsArtery surgeryAspirin useCoronary surgeryMulticenter RCTClinical featuresAttack TrialClinical centersClinical conditionsTreatment groupsPatientsBenefit of propranololClinical decisionTrial resultsHeterogeneous groupPropranololRCTsSurgeryTreatmentTrialsOverall benefit
1995
Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease
Price L, Spencer D, Marek K, Robbins R, Leranth C, Farhi A, Naftolin F, Roth R, Bunney B, Hoffer P, Makuch R, Redmond D. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biological Psychiatry 1995, 38: 498-505. PMID: 8562661, DOI: 10.1016/0006-3223(95)00129-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBrain Tissue TransplantationCaudate NucleusDepressive DisorderDopamineFemaleFetal Tissue TransplantationFollow-Up StudiesHumansMaleMesencephalonMiddle AgedNeurocognitive DisordersNeuropsychological TestsPanic DisorderParkinson DiseasePostoperative ComplicationsProspective StudiesConceptsParkinson's diseasePsychiatric statusHuman fetal mesencephalic tissueAdrenal medullary graftsAdrenal medullary transplantationFetal mesencephalic tissueSystematic psychiatric assessmentPerioperative sequelaeMesencephalic tissuePsychiatric sequelaeCaudate nucleusPsychiatric assessmentNeurobiological effectsBehavioral symptomsTissue transplantationDiseasePatientsTransplantationSequelaeSuch episodesEpisodesGroup effectsStatusDeliriumDiscrete episodes
1993
Low-grade astrocytomas may arise from different astrocyte lineages.
Piepmeier J, Fried I, Makuch R. Low-grade astrocytomas may arise from different astrocyte lineages. Neurosurgery 1993, 33: 627-32. PMID: 8232801, DOI: 10.1227/00006123-199310000-00010.Peer-Reviewed Original ResearchConceptsLow-grade astrocytomasGlial fibrillary acidic protein-positive cellsFibrillary acidic proteinProtein-positive cellsAstrocyte lineagePreoperative symptomsAnti-glial fibrillary acidic proteinAcidic proteinGlial fibrillary acidic proteinLong preoperative historyCommon histological featuresDifferent clinical manifestationsPercentage of cellsPreoperative historyClinical manifestationsHistological featuresImaging featuresRate of proliferationImmunohistochemical analysisAstrocytic phenotypeNeoplastic cellsType 2White matterAstrocytomasTumorsA phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
Murren J, Ganpule S, Papac R, Son Y, Peschel R, Durivage H, Buzaid A, Lamb L, Makuch R, Hait W. A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 1993, 5: 53-7. PMID: 8395915.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerMedian survival timeMitomycin CComplete respondersLung cancerSurvival timeUnresectable stage III non-small cell lung cancerStage III non-small cell lung cancerUnresectable non-small cell lung cancerDay 1Concurrent mitomycin CPhase II trialOverall response rateX-irradiationModerate stomatitisSustained remissionII trialSplit courseWeek restMedian durationContinuous infusionSimultaneous administrationRadiation therapyResponse rate
1992
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
Spencer D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B, Sass K, Elsworth J, Kier E, Makuch R, Hoffer P, Redmond D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. New England Journal Of Medicine 1992, 327: 1541-1548. PMID: 1435880, DOI: 10.1056/nejm199211263272201.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdultAntiparkinson AgentsCaudate NucleusCryopreservationCyclosporineDopamineFemaleFetal Tissue TransplantationHomovanillic AcidHumansMagnetic Resonance ImagingMaleMesencephalonMiddle AgedMotor ActivityParkinson DiseasePutamenStereotaxic TechniquesTomography, Emission-ComputedConceptsCase patientsParkinson's diseaseMesencephalic tissueCaudate nucleusHuman fetal ventral mesencephalic tissueFetal ventral mesencephalic tissueHuman fetal mesencephalic tissueContinued disease progressionFetal dopaminergic neuronsFetal mesencephalic tissueVentral mesencephalic tissueSevere Parkinson's diseaseOptimal drug therapySigns of parkinsonismMidbrain dopamine neuronsPositron emission tomographyMonths of evaluationAntiparkinsonian medicationUnilateral transplantationDrug holidayMore medicationsStriatonigral degenerationNeurologic functionDopaminergic neuronsDrug therapy
1991
High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma
Murren J, Derosa W, Durivage H, Davis C, Makuch R, Portlock C. High‐dose cisplatin plus dacarbazine in the treatment of metastatic melanoma. Cancer 1991, 67: 1514-1517. PMID: 2001539, DOI: 10.1002/1097-0142(19910315)67:6<1514::aid-cncr2820670609>3.0.co;2-q.Peer-Reviewed Original Research
1990
A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients
Roberts R, Jurica K, Meyer W, Paxton H, Makuch R. A Phase 1 Study of Ribavirin in Human Immunodeficiency Virus-Infected Patients. The Journal Of Infectious Diseases 1990, 162: 638-642. PMID: 2117625, DOI: 10.1093/infdis/162.3.638.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPhase 1 studyDaily dosesAdverse reactionsTreatment groupsHuman immunodeficiency virus-infected patientsPatients' peripheral blood mononuclear cellsHIV surrogate markersT lymphocyte subsetsVirus-infected patientsClinical adverse reactionsAnti-HIV effectDemonstrable beneficial effectsHuman immunodeficiency virusBlood mononuclear cellsOral ribavirinP24 antigenemiaLymphocyte subsetsTotal lymphocytesSerum betaImmunodeficiency virusLymphocyte markersMononuclear cellsLymphocyte populationsSurrogate markerTen-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation.
Johnson B, Grayson J, Makuch R, Linnoila R, Anderson M, Cohen M, Glatstein E, Minna J, Ihde D. Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Journal Of Clinical Oncology 1990, 8: 396-401. PMID: 2155310, DOI: 10.1200/jco.1990.8.3.396.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerLung cancerLung cancer 2Initiation of chemotherapyTen-year survivalCell lung cancerTherapeutic clinical trialsCranial irradiationCombination chemotherapyOriginal malignancySecond cancersClinical trialsHigh riskPatientsCancer 2CancerChemotherapyMalignancyMore yearsCauseYearsChestDiagnosisTrialsA multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy
Roberts R, Hollinger F, Parks W, Rasheed S, Laurence J, Heseltine P, Makuch R, Lubina J, Johnson K, Group R. A multicenter clinical trial of oral ribavirin in HIV-infected people with lymphadenopathy. AIDS 1990, 4: 67-72. PMID: 1690551, DOI: 10.1097/00002030-199001000-00009.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAIDS-Related ComplexDouble-Blind MethodFemaleGene Products, gagHIVHIV AntigensHIV Core Protein p24HIV InfectionsHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesRNA-Directed DNA PolymeraseUnited StatesViral Core ProteinsConceptsOral ribavirinPeripheral blood mononuclear cellsPlacebo-controlled trialBlood mononuclear cellsMulticenter clinical trialHIV isolationP24 antigenemiaStudy drugMulticenter trialActive treatmentDaily dosesMononuclear cellsClinical trialsMedical CenterWeek 6HIV activityAdult menRibavirinTrialsLymphadenopathyHIVInterlaboratory variationCritical roleAntigenemiaPlaceboA multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference
1988
A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients
Messerschmidt G, Makuch R, Appelbaum F, Ungerleider R, Abrams R, O'Donnell J, Holohan T, Fontana J, Wright D, Anagnou N, Shan T, Chesbro B, Deisseroth A. A prospective randomized trial of HLA‐matched versus mismatched single‐donor platelet transfusions in cancer patients. Cancer 1988, 62: 795-801. PMID: 3293762, DOI: 10.1002/1097-0142(19880815)62:4<795::aid-cncr2820620426>3.0.co;2-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAmbulatory CareAntibody FormationBlood DonorsBlood PlateletsBlood TransfusionChildChild, PreschoolClinical Trials as TopicFemaleHemorrhageHistocompatibility TestingHumansInfantMaleMiddle AgedNeoplasmsPlatelet TransfusionProspective StudiesRandom AllocationThrombocytopeniaTransfusion ReactionConceptsSingle-donor platelet transfusionsPlatelet transfusionsCancer patientsFebrile patientsPosttransfusion incrementsThrombocytopenic cancer patientsTransfusion of HLASevere bleeding episodesMulti-institution trialNonfebrile patientsIntensive chemotherapyBleeding episodesAntiplatelet antibodiesAntibody titersSignificant thrombocytopeniaHistocompatability antigensTransfusionPatientsMismatched groupHLAThrombocytopeniaPlateletsEpisodesSeparate episodesTrials